Lazarus Rochelle B - Jun 10, 2022 Form 4 Insider Report for Organon & Co. (OGN)

Role
Director
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Rochelle B. Lazarus
Stock symbol
OGN
Transactions as of
Jun 10, 2022
Transactions value $
$199,994
Form type
4
Date filed
6/14/2022, 07:34 PM
Previous filing
Jul 13, 2021
Next filing
Jul 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
holding OGN Common Stock 458 Jun 10, 2022 Direct F1
holding OGN Common Stock 175 Jun 10, 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Phantom Stock +Grant/Award $199,994 +5,640 +62.68% $35.46 14,638 Jun 10, 2022 Common Stock 5,640 Direct F2, F3, F4

Explanation of Responses:

Id Content
F1 The number of shares of Organon & Co. ("Organon") common stock previously reported has been adjusted based on the finalization of certain calculations in connection with the separation of Organon from Merck & Co., Inc.
F2 Each phantom stock unit is an economic equivalent of one share of Organon common stock, or 1-for-1.
F3 Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan.
F4 Holdings include phantom stock acquired in dividend reinvestment transactions on September 13, 2021, December 16, 2021 and March 17, 2022.